CTIC — CTI Biopharma Share News
0.000.00%
Last trade - 00:00HealthcareSpeculativeMid Cap
- $1.20bn
- $1.26bn
- $53.95m
Brief: Dri Healthcare Trust Says Approval Of Pacritinib By FDA Is Condition To Acquisition Of Tiered Royalty On Pacritinib
Brief: CTI Biopharma Announces Extension Of FDA Review Period For Pacritinib
CTI Biopharma Corp reports results for the quarter ended in September - Earnings Summary
CTI BioPharma drops after COVID-19 drug fails clinical study
Brief: Cti Biopharma Announces Topline Data From Final Analysis Of The Pre-Vent Clinical Trial Evaluating Pacritinib As A Treatment For Severe Covid-19
CTI BioPharma rises on funding for launch of cancer drug
Brief: CTI Biopharma And DRI Healthcare Announce Up To $135 Mln Transaction
CTI Biopharma Corp reports results for the quarter ended in June - Earnings Summary
Brief: CTI Biopharma Q2 Loss Per Share $0.21
CTI Biopharma Corp expected to post a loss of 21 cents a share - Earnings Preview
Brief: CTI BioPharma Q1 Loss Per Share $0.23
Brief: Cti Biopharma Announces Acceptance Of NDA Granted With Priority Review Of Pacritinib For Treatment Of Patients With Myelofibrosis
CTI Biopharma Corp expected to post a loss of 22 cents a share - Earnings Preview
CTI Biopharma Corp reports results for the quarter ended in March - Earnings Summary
CTI BioPharma down on $50 mln stock offering
Brief: CTI Biopharma Corp Announces Pricing Of Its Public Offering Of Common Stock And Preferred Stock
Brief: CTI Biopharma Corp Announces Proposed Public Offering Of Common Stock And Preferred Stock
Brief: CTI Biopharma Says Phase 1 Trial Shows Encouraging Clinical Benefit And Promising Safety Profile Of Pacritinib
U.S. STOCKS ON THE MOVE-Tesla, Applied Materials, SVB Financial, Support.Com